<DOC>
	<DOCNO>NCT00053560</DOCNO>
	<brief_summary>The purpose clinical trial study effect GL701 bone mineral density woman active systemic lupus erythematosus ( SLE ) also receive treatment glucocorticoid ( e.g. , prednisone ) .</brief_summary>
	<brief_title>To Assess Prevention Bone Loss Women With Lupus Receiving Treatment With Glucocorticoids</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>INCLUSION CRITERIA Women least 18 year age . Meet ACR criterion diagnosis SLE . Concomitant treatment prednisone dose ≥5 mg/day last 30 day prior Screening visit . Cumulative history oral glucocorticoid use least 6 month last year prior Screening Visit ( 6 month consecutive ) . Patient lumbar spine proximal femur anatomy suitable measurement DXA least 3 evaluable vertebra L1 L4 . SLEDAI ≥3 Qualifying Visit . Women childbearing potential must negative serum pregnancy test ( Screening Visit ) agree use reliable form birth control participate study . Patient fully ambulatory . Patient read sign Informed Consent Form . EXCLUSION CRITERIA History breast cancer malignancy reproductive tract organ . History cancer unless evidence disease 5 year . History endometrial hyperplasia . End stage renal disease receive hemodialysis treatment . Any disease condition would preclude accurate measurement bone mineral density lumbar spine proximal femur dual Xray absorptiometry . A Tscore less equal 2.5 Lspine proximal femur Screening DXA assessment . Unstable cardiac disease . Conditions cause bone loss hyperparathyroidism , Cushing 's disease , thyrotoxicosis , chronic diarrheal state malabsorption , renal tubular acidosis , anorexia nervosa . Significant hepatic disease ( i.e. , cirrhosis ) . Body mass index &gt; 35 kg/m2 weight &gt; 300 lb . Patients pregnant breast feed . Patients require glucocorticoid alternate day dose schedule . Known hypersensitivity DHEA , inactive ingredient use GL701 formulation ( cornstarch , lactose , magnesium stearate ) . Known medical contraindication hypersensitivity Calcium/Vitamin D. Participation prior DHEA GL701 study . Use investigational agent within 30 day Screening Visit 10 halflives agent . Any condition Investigator 's Sponsor 's opinion sufficient prevent adequate compliance study likely confuse followup evaluation ( e.g. , alcoholism , drug addiction , acute withdrawal chemical dependency , psychiatric disease ) . The patient take take one medication list : ANTIRESORPTIVES : Use calcitonin within 30 day prior Screening Visit . Fluorides &gt; 1 mg/day time prior study . Strontium pharmacologic dose time . BISPHOSPHONATE USE follow : Any use within 90 day prior Screening Visit . ≥ 2 week use last year prior Screening Visit . ≥ 3 month use last 2 year prior Screening Visit . ≥ 1 intravenous dose last 2 year prior Screening Visit . ≥ 6 month lifetime exposure prior Screening Visit . ESTROGENIC STEROIDS ( Except oral contraceptive ) : Estrogenic steroid ( HRT ) within 60 day Screening Visit . Selective estrogen receptor modulator ( raloxifene ) within 60 day Screening Visit . OTHER HORMONES : Parathyroid hormone ( PTH ) within six month Screening Visit . Use androgens , include prescription nutritional supplement DHEA , within 30 day Screening Visit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>lupus</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>SLE</keyword>
	<keyword>bone loss</keyword>
	<keyword>DHEA</keyword>
</DOC>